Index -
P/E -
EPS (ttm) -0.61
Insider Own 8.38%
Shs Outstand 64.39M
Perf Week -3.06%
Market Cap 10.63M
Forward P/E -
EPS next Y -0.09
Insider Trans -26.51%
Shs Float 59.08M
Perf Month -10.92%
Income -39.11M
PEG -
EPS next Q -0.11
Inst Own 35.46%
Short Float 3.27%
Perf Quarter -35.95%
Sales 0.01M
P/S 1062.63
EPS this Y 12.93%
Inst Trans -1.73%
Short Ratio 0.52
Perf Half Y -94.28%
Book/sh 0.31
P/B 0.53
EPS next Y 82.18%
ROA -90.71%
Short Interest 1.93M
Perf Year -88.14%
Cash/sh 0.35
P/C 0.47
EPS next 5Y -
ROE -104.49%
52W Range 0.16 - 3.53
Perf YTD -93.02%
Dividend Est. -
P/FCF -
EPS past 5Y 13.11%
ROI -194.96%
52W High -95.33%
Beta 2.05
Dividend TTM -
Quick Ratio 5.48
Sales past 5Y -53.76%
Gross Margin -3102.77%
52W Low 6.32%
ATR (14) 0.01
Dividend Ex-Date -
Current Ratio 5.48
EPS Y/Y TTM 7.48%
Oper. Margin -408772.17%
RSI (14) 41.58
Volatility 6.81% 7.38%
Employees 35
Debt/Eq 0.02
Sales Y/Y TTM -86.67%
Profit Margin -391135.91%
Recom 3.00
Target Price 0.50
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -21.87%
Payout -
Rel Volume 0.11
Prev Close 0.17
Sales Surprise -
EPS Surprise 7.46%
Sales Q/Q -
Earnings Aug 01
Avg Volume 3.71M
Price 0.16
SMA20 -2.94%
SMA50 -20.22%
SMA200 -88.94%
Trades
Volume 395,659
Change -3.06%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-26-24 Downgrade
TD Cowen
Buy → Hold
Dec-22-23 Initiated
CapitalOne
Overweight
$12
Nov-12-21 Upgrade
Jefferies
Hold → Buy
$3 → $4
Nov-14-19 Initiated
ROTH Capital
Buy
$12
Aug-05-19 Downgrade
SunTrust
Buy → Hold
$23 → $5
Aug-05-19 Downgrade
Piper Jaffray
Overweight → Neutral
$20 → $6
Aug-05-19 Downgrade
Jefferies
Buy → Hold
Apr-12-19 Initiated
Piper Jaffray
Overweight
$20
Dec-18-18 Initiated
H.C. Wainwright
Buy
$24
Jul-26-16 Initiated
SunTrust
Buy
Mar-17-15 Reiterated
Stifel
Buy
$13 → $14
Show Previous Ratings
Jul-25-24 09:00AM
Jul-22-24 07:00AM
Jun-26-24 07:41AM
Jun-25-24 07:37AM
Jun-04-24 07:00AM
04:01PM
Loading…
May-29-24 04:01PM
May-28-24 04:05AM
May-09-24 10:58PM
07:19PM
(Associated Press Finance)
May-08-24 07:42AM
May-07-24 05:21AM
May-06-24 03:53PM
12:45PM
08:40AM
07:52AM
07:28AM
Loading…
07:28AM
06:00AM
Apr-25-24 07:00AM
Mar-28-24 10:12AM
02:10AM
(Thomson Reuters StreetEvents)
Mar-27-24 11:53AM
10:31AM
07:14AM
(Associated Press Finance)
07:00AM
Mar-21-24 08:50AM
Mar-13-24 07:00AM
Feb-26-24 07:00AM
Feb-12-24 07:00AM
Jan-04-24 07:00AM
Jan-03-24 07:00AM
12:00PM
Loading…
Dec-10-23 12:00PM
Nov-09-23 07:00AM
Nov-05-23 08:51AM
Nov-04-23 01:48AM
(Thomson Reuters StreetEvents)
Nov-03-23 10:33AM
07:07AM
(Associated Press Finance)
07:00AM
Oct-23-23 08:30AM
Oct-20-23 07:00AM
Sep-06-23 07:00AM
Sep-05-23 07:00AM
Aug-17-23 07:00AM
Aug-02-23 07:17AM
(Associated Press Finance)
07:00AM
Jul-19-23 07:00AM
Jul-13-23 09:29AM
Jun-26-23 08:00AM
Jun-15-23 08:00AM
Jun-12-23 11:13AM
May-31-23 07:00AM
May-16-23 10:37AM
May-03-23 10:17PM
(Thomson Reuters StreetEvents)
+7.35%
07:23AM
07:00AM
Apr-26-23 07:00AM
Apr-19-23 10:20AM
Apr-05-23 01:45PM
Mar-31-23 04:30AM
Mar-29-23 07:00AM
Mar-21-23 06:23AM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 07:00AM
06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 07:00AM
06:01AM
06:01AM
Feb-28-23 06:43AM
Feb-27-23 06:50AM
Feb-24-23 07:17AM
07:17AM
Feb-16-23 08:00AM
Feb-15-23 08:00AM
Feb-14-23 06:23AM
Feb-06-23 07:00AM
Jan-22-23 07:30AM
07:24AM
Dec-30-22 07:17AM
Dec-28-22 06:58AM
Dec-26-22 07:14AM
Dec-19-22 09:40AM
Dec-12-22 07:00AM
Dec-02-22 01:18PM
09:40AM
Nov-23-22 09:55AM
Nov-16-22 09:40AM
Nov-12-22 07:14AM
Nov-10-22 09:12AM
(Simply Wall St.) +19.48%
Nov-09-22 07:00AM
Nov-08-22 04:05PM
Nov-03-22 09:00AM
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Invus Public Equities, L.P. 10% Owner Aug 08 '24 Sale 0.19 260,873 50,009 6,317,565 Aug 09 04:30 PM Invus Public Equities, L.P. 10% Owner Aug 07 '24 Sale 0.18 61,488 11,197 6,578,438 Aug 09 04:30 PM Invus Public Equities, L.P. 10% Owner Aug 05 '24 Sale 0.19 164,523 30,996 6,695,658 Aug 07 04:30 PM Invus Public Equities, L.P. 10% Owner Aug 06 '24 Sale 0.18 55,732 10,188 6,639,926 Aug 07 04:30 PM Invus Public Equities, L.P. 10% Owner Aug 02 '24 Sale 0.20 286,200 57,354 6,860,181 Aug 05 04:53 PM Invus Public Equities, L.P. 10% Owner Aug 01 '24 Sale 0.22 63,564 13,743 7,146,381 Aug 05 04:53 PM Invus Public Equities, L.P. 10% Owner Jul 30 '24 Sale 0.22 756,835 167,185 7,209,945 Jul 30 05:16 PM Invus Public Equities, L.P. 10% Owner Jul 29 '24 Sale 0.24 363,949 85,637 7,966,780 Jul 30 05:16 PM Invus Public Equities, L.P. 10% Owner Jul 26 '24 Sale 0.24 258,335 62,440 8,330,729 Jul 30 05:16 PM Rock Edwin Chief Medical Officer Jun 20 '24 Buy 0.25 190,000 48,108 565,403 Jun 24 04:29 PM Rock Edwin Chief Medical Officer Jun 21 '24 Buy 0.27 115,000 30,716 680,403 Jun 24 04:29 PM Hahn Brian M. SVP Finance, CFO Jun 18 '24 Buy 0.25 17,500 4,335 70,643 Jun 20 04:15 PM Rock Edwin Chief Medical Officer Sep 21 '23 Buy 1.38 35,000 48,300 345,000 Sep 25 04:21 PM Rock Edwin Chief Medical Officer Sep 22 '23 Buy 1.38 30,403 41,956 375,403 Sep 25 04:21 PM
Index RUT
P/E -
EPS (ttm) -2.33
Insider Own 18.31%
Shs Outstand 75.98M
Perf Week 9.57%
Market Cap 751.48M
Forward P/E -
EPS next Y -1.98
Insider Trans -0.16%
Shs Float 65.38M
Perf Month 1.40%
Income -203.85M
PEG -
EPS next Q -0.58
Inst Own 95.23%
Short Float 24.33%
Perf Quarter 11.12%
Sales 0.00M
P/S -
EPS this Y -13.00%
Inst Trans -2.45%
Short Ratio 20.34
Perf Half Y -45.41%
Book/sh 1.67
P/B 5.62
EPS next Y 11.78%
ROA -79.66%
Short Interest 15.91M
Perf Year 34.91%
Cash/sh 2.38
P/C 3.94
EPS next 5Y -
ROE -121.29%
52W Range 6.03 - 21.17
Perf YTD -50.05%
Dividend Est. -
P/FCF -
EPS past 5Y 8.79%
ROI -105.14%
52W High -55.64%
Beta 0.83
Dividend TTM -
Quick Ratio 6.04
Sales past 5Y -5.25%
Gross Margin -
52W Low 55.72%
ATR (14) 0.64
Dividend Ex-Date -
Current Ratio 6.04
EPS Y/Y TTM -2.48%
Oper. Margin 0.00%
RSI (14) 57.67
Volatility 8.80% 7.17%
Employees 150
Debt/Eq 0.51
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.00
Target Price 27.86
Option/Short Yes / Yes
LT Debt/Eq 0.45
EPS Q/Q -27.65%
Payout -
Rel Volume 2.67
Prev Close 8.51
Sales Surprise -
EPS Surprise -1.63%
Sales Q/Q -
Earnings Aug 08 BMO
Avg Volume 782.19K
Price 9.39
SMA20 7.30%
SMA50 5.27%
SMA200 -27.10%
Trades
Volume 2,086,151
Change 10.34%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-28-24 Initiated
Raymond James
Strong Buy
$30
Oct-25-23 Upgrade
Jefferies
Hold → Buy
$20
Apr-03-23 Resumed
Piper Sandler
Overweight
$26
Sep-19-22 Resumed
H.C. Wainwright
Buy
$30
Jul-12-22 Initiated
Truist
Buy
$20
Mar-23-22 Initiated
H.C. Wainwright
Buy
$24
Dec-22-21 Downgrade
Jefferies
Buy → Hold
$52 → $28
Nov-19-21 Initiated
Piper Sandler
Overweight
$56
Apr-26-21 Resumed
Credit Suisse
Outperform
$65
Jan-11-21 Initiated
Credit Suisse
Outperform
$65
Jan-06-21 Initiated
JP Morgan
Overweight
$59
Mar-12-20 Initiated
Robert W. Baird
Outperform
$35
Show Previous Ratings
Sep-13-24 04:15PM
Sep-10-24 08:00AM
Sep-05-24 12:02AM
Sep-04-24 08:00AM
Sep-02-24 05:22PM
08:00AM
Loading…
Aug-29-24 08:00AM
Aug-16-24 04:15PM
Aug-15-24 04:32AM
Aug-09-24 05:05AM
(Thomson Reuters StreetEvents)
Aug-08-24 07:00AM
Jul-23-24 08:00AM
Jul-12-24 04:15PM
Jul-08-24 06:42PM
12:30PM
Jun-24-24 07:00AM
04:15PM
Loading…
Jun-18-24 04:15PM
Jun-03-24 04:00PM
May-28-24 08:00AM
May-22-24 07:00AM
May-20-24 08:00AM
May-17-24 04:15PM
May-14-24 08:00AM
May-07-24 01:53PM
10:19AM
08:52AM
07:00AM
Apr-24-24 06:33AM
Apr-12-24 04:15PM
Mar-20-24 05:31AM
Mar-19-24 10:52PM
07:00AM
Loading…
07:00AM
Mar-15-24 04:15PM
08:18AM
Feb-28-24 08:00AM
Feb-16-24 04:15PM
Feb-15-24 08:00AM
Feb-06-24 08:00AM
Jan-25-24 08:00AM
Jan-23-24 08:00AM
Jan-22-24 07:00AM
(The Wall Street Journal)
Jan-18-24 05:01PM
Jan-12-24 04:15PM
Jan-04-24 08:00AM
Jan-02-24 01:57PM
Dec-30-23 07:01PM
Dec-19-23 08:00AM
Dec-15-23 04:15PM
Dec-10-23 09:05AM
Nov-17-23 04:15PM
Nov-12-23 12:32PM
Nov-07-23 08:14AM
07:15AM
Nov-06-23 09:55AM
Nov-03-23 11:52PM
04:00PM
Nov-02-23 08:00AM
Oct-31-23 08:50AM
Oct-24-23 12:00PM
Oct-23-23 08:00AM
Oct-19-23 09:55AM
08:00AM
Oct-18-23 08:30AM
Oct-16-23 04:15PM
(Business Wire) +5.36%
+5.33%
Oct-13-23 12:45PM
Oct-12-23 04:17PM
Oct-11-23 08:57PM
05:05PM
04:44PM
Sep-19-23 08:00AM
Sep-15-23 04:15PM
Sep-07-23 09:55AM
Aug-18-23 04:15PM
Aug-09-23 04:15PM
Aug-02-23 10:41AM
Jul-13-23 08:00AM
Jun-30-23 11:00AM
Jun-15-23 08:00AM
Jun-01-23 04:05PM
May-10-23 08:00AM
May-09-23 07:30AM
May-08-23 08:00AM
Apr-17-23 12:57PM
Apr-12-23 08:00AM
Apr-10-23 04:05PM
Mar-15-23 08:00AM
Mar-07-23 07:00AM
Mar-01-23 08:00AM
Feb-27-23 08:00AM
Feb-17-23 08:00AM
Feb-11-23 07:23AM
Feb-06-23 08:00AM
Jan-09-23 08:00AM
Jan-03-23 08:00AM
Nov-16-22 06:04AM
Nov-15-22 08:00AM
Nov-14-22 08:00AM
Nov-10-22 09:00AM
Nov-09-22 08:00AM
Nov-08-22 08:00AM
Oct-22-22 07:00AM
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Qatanani Mo CHIEF SCIENTIFIC OFFICER Sep 16 '24 Sale 8.58 1,936 16,611 142,768 Sep 19 08:15 AM Parlavecchio Caryn CHRO Aug 16 '24 Sale 9.33 1,451 13,538 151,988 Aug 19 05:00 PM Qatanani Mo CHIEF SCIENTIFIC OFFICER Jun 17 '24 Sale 8.98 2,315 20,800 144,704 Jun 18 05:56 PM Parlavecchio Caryn CHRO Jun 17 '24 Sale 8.98 4,305 38,680 153,439 Jun 18 05:55 PM Myles Edward H COO & CFO Jun 17 '24 Sale 8.98 9,458 84,978 201,518 Jun 18 05:54 PM Ho Junlin GENERAL COUNSEL Jun 17 '24 Sale 8.98 4,695 42,183 204,076 Jun 18 05:53 PM Myles Edward H COO & CFO Feb 16 '24 Sale 15.74 4,744 74,686 210,976 Feb 21 06:13 PM Qatanani Mo CHIEF SCIENTIFIC OFFICER Feb 16 '24 Sale 15.74 2,512 39,547 147,019 Feb 20 04:58 PM Parlavecchio Caryn CHRO Feb 16 '24 Sale 15.74 3,751 59,053 157,744 Feb 20 04:52 PM Ho Junlin GENERAL COUNSEL Feb 16 '24 Sale 15.74 3,489 54,928 208,771 Feb 20 04:48 PM Backstrom Jay T. CHIEF EXECUTIVE OFFICER Feb 16 '24 Sale 15.74 11,614 182,842 352,671 Feb 20 04:46 PM Qatanani Mo SVP AND HEAD OF RESEARCH Jan 16 '24 Sale 15.93 2,002 31,889 78,816 Jan 18 04:11 PM Parlavecchio Caryn CHRO Jan 16 '24 Sale 15.93 2,849 45,381 114,350 Jan 18 04:08 PM Myles Edward H COO & CFO Jan 16 '24 Sale 15.93 6,634 105,670 162,150 Jan 18 04:07 PM Ho Junlin GENERAL COUNSEL Jan 16 '24 Sale 15.93 4,186 66,677 154,405 Jan 18 04:05 PM Myles Edward H COO & CFO Dec 29 '23 Option Exercise 4.86 12,459 60,551 181,243 Dec 29 07:13 PM Myles Edward H COO & CFO Dec 29 '23 Sale 18.83 12,459 234,633 168,784 Dec 29 07:13 PM Qatanani Mo SVP AND HEAD OF RESEARCH Dec 14 '23 Option Exercise 10.00 8,437 84,370 105,480 Dec 15 04:13 PM Qatanani Mo SVP AND HEAD OF RESEARCH Dec 14 '23 Sale 18.18 24,662 448,444 80,818 Dec 15 04:13 PM Myles Edward H COO & CFO Dec 07 '23 Option Exercise 4.86 24,914 121,082 193,698 Dec 08 04:12 PM Myles Edward H COO & CFO Dec 07 '23 Sale 17.53 24,914 436,820 168,784 Dec 08 04:12 PM Myles Edward H COO & CFO Nov 02 '23 Sale 12.51 35,007 438,039 168,784 Nov 03 06:11 PM AKKARAJU SRINIVAS Director Oct 16 '23 Buy 6.85 2,189,781 15,000,000 6,788,609 Oct 18 05:46 PM Samsara BioCapital GP, LLC 10% Owner Oct 16 '23 Buy 6.85 2,189,781 15,000,000 6,788,609 Oct 18 05:44 PM Invus Public Equities, L.P. 10% Owner Oct 12 '23 Buy 6.86 2,199,931 15,086,736 11,259,438 Oct 16 05:46 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite